Skip to main content
. Author manuscript; available in PMC: 2016 Jun 3.
Published in final edited form as: Gynecol Oncol. 2014 Dec 17;136(3):542–548. doi: 10.1016/j.ygyno.2014.12.017

Table 1.

Gene-level AML test and most significantly associated SNP (MAFa ≥ 0.05) in each gonadotropin signaling gene for all invasive ovarian cancers.

Gene Coverage (at imputation r2 = 0.8) Number of SNPs Number of significant SNPs (at =0.05) AML burden testb Most significant SNP MAFa Imputation r2 ORc p-Value
ACVR1 0.55 101 1 0.73 rs35160507 0.07 0.77 1.07 0.030
ACVR2 0.98 163 1 0.52 rs17742573 0.07 0.56 0.93 0.046
CGA 0.97 140 15 0.29 rs7745823 0.24 0.83 0.96 0.035
FSHB 0.99 111 18 0.036 rs12805742 0.22 0.94 1.04 0.018
FSHR 0.90 746 15 0.57 chr2:49204261:D 0.07 0.70 0.91 0.007
GNRH 1.00 108 0 0.65 N/A
GNRHR 0.94 126 0 0.59 N/A
INHA 0.86 81 15 0.060 rs12720063 0.21 1.00 0.95 0.007
INHBA 1.00 77 1 0.80 rs17776182 0.15 1.00 0.95 0.010
INHBB 0.82 109 22 0.098 rs11900747 0.06 0.55 1.13 0.004
LHCGR 0.97 423 52 0.091 rs72618637 0.19 0.68 1.07 0.001
Global 2185 140 0.33

Note: “N/A” reflects genes with no significant SNPs at p ≥ 0.05. “Global” refers to when all genes are considered.

a

MAF = minor allele frequency.

b

AML = admixture maximum likelihood, taking into account the first five ancestry principal components; p-values for trend reported.

c

OR = per allele odds ratio, taking into account study set and the first five ancestry principal components.